InflaRx registers up to $65 million in ordinary shares for at-the-market salesAug 14FinancingInflaRx N.V.
InflaRx weighs broader EU strategy for vasculitis drugs after Tavneos setbackJun 30Regulatory decisionavacopanInflaRx N.V.
Sign in